Tumor Purity-Related Genes for Predicting the Prognosis and Drug Sensitivity

of DLBCL Patients

Zhenbang Ye[1#], Ning Huang[2#], Yongliang Fu[1], Rongle Tian[1], Wenting Huang[1,3*]

[1]Department of Pathology, National Cancer Center/National Clinical Research Center for

Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical

College, Beijing, China;

[2]Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center

for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical

College, Beijing 100021, China

[3]Department of Pathology, National Cancer Center/National Clinical Research Center for

Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking

Union Medical College, Shenzhen, 518116, China.

#These authors contributed equally to this work.

*Corresponding author

Wenting Huang, Ph.D.

Department of Pathology, National Cancer Center/National Clinical Research Center for

Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical

College, Beijing, China; No. 17 Panjiayuan Nanli, Chaoyang Dist., Beijing, PRC.

Department of Pathology, National Cancer Center/National Clinical Research Center for

Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking

Union Medical College, Shenzhen, 518116, China; No. 113 Baohe Ave. Longgang Dist. Shenzhen,

PRC.

E-mail: huangwt@cicams.ac.cn

Abstract

Background: Diffuse large B-cell lymphoma (DLBCL) is the predominant type of malignant

B-cell lymphoma. Although various treatments have been developed, the limited efficacy calls for

more and further exploration of its characteristics.

Methods: Datasets from Gene Expression Omnibus (GEO) database were used for identifying the

tumor purity of DLBCL. Survival analysis was employed for analyzing the prognosis of DLBCL

patients. Immunohistochemistry was conducted to detect the important factor that influenced the

prognosis. Drug sensitive prediction was performed to evaluate the value of the constructed

model.

Results: VCAN, CD3G and C1QB were identified as three key genes that impacted the outcome

of DLBCL patients both in GEO datasets and samples from our center. Among them, VCAN and

CD3G+ T cells were correlated with favorable prognosis, and C1QB was correlated with worse

prognosis. The ratio of CD68+ macrophages and CD8+ T cells was associated with better

prognosis. In addition, CD3G+ T cells ratio was significantly correlated with CD68+ macrophages,

CD4+ T cells and CD8+ T cells ratio, indicating it could play an important role in the anti-tumor

immunity in DLBCL. The riskScore model constructed based on the RNASeq data of VCAN,

C1QB and CD3G work well in predicting the prognosis and drug sensitivity.

Conclusion: VCAN, CD3G and C1QB were three key genes that influenced the tumor purity of

DLBCL, and could also exert certain impact on drug sensitivity and prognosis of DLBCL patients.

Keywords: DLBCL, tumor purity, VCAN, CD3G, C1QB

Introduction

The latest refined classification by the World Health Organization (WHO) categorizes large B-cell

lymphoma as a heterogeneous group of B-cell lymphomas[1]. Diffuse large B-cell lymphoma

(DLBCL) is the most prevalent type among them, accounting for around 30% of all non-Hodgkin

lymphomas. DLBCL can be classified into three subtypes based on its immunohistochemical

expression patterns: germinal center B-cell-like (GCB), activated B-cell-like (ABC), and

unclassified[2]. After undergoing R-CHOP chemotherapy, about 60% of patients achieve

long-term remission; however, approximately 30% of patients experience relapse, resulting in

poor prognosis and a considerable number of deaths from refractory lymphoma[3]. Consequently,

to explore the characteristics of DLBCL in detail is urgently needed for developing more effective

therapy.

Solid tumor tissue comprises tumor cells and the surrounding stroma, which encompasses

diverse types of matrix cells, immune cells, endothelial cells[4], etc. The tumor microenvironment

(TME) is a complex and dynamic system that consists of the extracellular matrix and a variety of

cellular components. Recent studies have unveiled multiple subgroups of immune cells within the

microenvironment of DLBCL, including T cells, B cells, NK cells, monocytes/macrophages,

dendritic cells, as well as the distribution of stromal cell components like fibroblasts and

endothelial cells[5, 6]. Despite the relatively limited composition of the TME in DLBCL, its role

in tumor proliferation and evasion of the immune system should not be disregarded. The

interaction between tumors and the microenvironment is a vital factor that impacts the

development and prognosis of B-cell lymphoma[7]. Nevertheless, the existing research on the

influence of the TME on the prognosis of DLBCL patients is limited and lacks a consensus.

Moreover, the comprehensive investigation of non-immune cell components in the TME is still

lacking. Previous research on stroma in DLBCL has predominantly indicated that a higher

quantity of extracellular matrix is associated with a more favorable prognosis, while increased

vascular density is associated with poorer prognosis[8]. Furthermore, higher stromal scores have

been associated with an improved prognosis in DLBCL patients[9]. Additionally, a fibrotic tumor

microenvironment has been correlated with a better prognosis after DLBCL chemotherapy and

immunotherapy[10]. These research findings stem from computational analysis of stromal and

immune scoring in gene databases and have not been experimentally validated as of yet.

Tumor purity quantifies the relative ratio of tumor cells to the surrounding stromal components

in solid tumors, elucidating the dynamics between tumor cells and their microenvironment[11]. It

can partly reflect the characteristics of TME, namely, a higher tumor purity indicates a lower

abundance of stromal components in TME. Tumor purity is associated with patient prognosis, and

the strength of this association varies across different tumor types[12-14]. Therefore, when

investigating the influence of TME on the prognosis of DLBCL, it is crucial to analyze not only

the immune cell components but also the significance of non-immune cell components.

This study utilized bioinformatic analysis to establish the relationship between immune and

stromal components and the prognostic outcomes of DLBCL patients. We developed a novel

immunohistochemical panel to assess prognostic outcomes and treatment sensitivity by detecting

the expression of VCAN, CD3G, C1QB, CD68, CD4 and CD8 in both the TME and tumor cells

of 190 DLBCL patients. We then explored their relationship with DLBCL clinicopathological

features as well as overall survival (OS).

Materials and Methods

Data collection and tumor purity-related genes (TPGs) selection

The RNA-Sequence and clinical data of GSE53786 and GSE32918 datasets were download from Gene Expression Omnibus (GEO) database. The first gene symbols of GSE53786 datasets were retained when one probe detected multiple genes. Average expression value of genes in each dataset were calculated and used when one gene was detected by multiple probes. Tumor purity was assessed by ESTIMATE (Estimation of Stromal and Immune cells in Malignant Tumor tissues using Expression data) algorithm and the then its correlation with genes expression was analyzed. The genes with $| r | \geq 0.5$ and p value < 0.05 was defined as the TPGs.

TPGs function analysis

Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were executed to analyze the biological processes, cellular components, molecular functions and pathways related to the TPGs. The statistical significance was considered as p.adjust < 0.05.

The protein-protein interactions (PPI) analysis was utilized to investigate the interaction among TPGs, and those with interactive confidence greater than 0.90 on the STRING platform (version 11.5) were selected to establish an interaction network with Cytoscape software (version 3.8.2).

Prognostic model

The prognostic model was constructed with "survival" package in R (version 4.1.3). The genes enrolled in this model was selected among the prognostic and PPI hub TPGs by function "step" in "survival" package, which can optimize the model. The prognostic model was represented by riskScore = $\sum_{i=1}^{n}$ gene expression$_i$ $\times$ coef$_i$.

Clinical specimens and follow-up

190 patients from Cancer hospital Chinese Academy of Medical Sciences, the CHCAMS cohort, were enrolled in this study (**Supplementary table 1**). All patients received surgery or biopsy during September, 2010 and September, 2020, and then standard follow-ups were carried out until March, 2023. The overall survival (OS) was defined as the interval between the operation and death or the last follow-up. The specimens from the CHCAMS cohort were used for

immunohistochemistry assay. The study was designed according to the Declaration of Helsinki and approved by the institutional ethics committee of Cancer Hospital Chinese Academy of Medical Sciences. Informed consent was taken from all the patients.

IHC

Paraffin embedded DLBCL tissues of CHCAMS Cohort were used for immunohistochemistry (IHC). After de-paraffinization and hydration, heat-induced method was performed for antigen retrieval. Primary antibody of VCAN (AB177480, 1:100, Abcam, USA), CD3G (AB134096, 1:1000, Abcam, USA), C1QB (AB92508, 1:50, Abcam, USA), CD68 (303565, 1:1000, Abcam, USA), CD4 (ZM-0418, ZSGB-BIO, China), CD8 (ZA-0508, ZSGB-BIO, China) was incubated at 4°C overnight. Sections were washed with TBS-T buffer, and then incubated with secondary antibody, and finally stained with DAB. The quantitative analysis of the slices was conducted by QuPath-0.4.3. VCAN and C1QB were assessed by H-score, and CD3G, CD68, CD4, CD8 were assessed as the ratio of the corresponding positive cells among all cells.

Drug sensitivity prediction

Drug sensitivity prediction was conducted utilizing "oncoPredict" packages in R 4.1.3. The drug sensitivity data was collected from Genomics of Drug Sensitivity in Cancer (GDSC). The drugs that was analyzed in this study was selected according to clinical practice or clinical trials searched in Pubmed.

Statistical analysis

Data in this study was shown in the form of mean ± SEM. Correlation between two variates was determined with Spearman analysis. Kaplan–Meier (K–M) curve and Log rank test were used for survival analysis. The cut-offs of survival analysis were provided by X-tile. The independent risk factor analysis was performed with Cox regression analysis. Receiver operating characteristic (ROC) curve was used for test the efficacy of prognostic model. The clinicopathological characteristics difference analysis was conducted with χ^2 test, Fisher's exact test or Wilcoxon rank sum test. The drug sensitivity scores were compared with Wilcoxon rank sum test. In this study, $p < 0.05$ were considered statistically significant.

Results

Tumor purity related genes were correlated with extracellular matrix organization and immune response

Based on GSE53786 dataset, we first assessed the tumor purity of DLBCL, which ranged from 17.2% to 67.4% (**Figure 1A**). In order to screen out the TPGs, we then analyzed the correlation between genes expression and tumor purity. According to the thresholds mentioned above, 642 genes were identified as TPGs, among which 31 genes were positively correlated with tumor purity, while 611 genes were negatively correlated with it (**Figure 1B**). In addition, tumor purity did have influence on the prognosis of DLBCL patients, which showed that patients with high tumor purity had lower OS rate than those with low tumor purity (**Figure 1C,** $p = 0.025$).

Next, we performed GO and KEGG enrichment analyses to explore the functions and signaling pathways in which these TPGs were involved. It turned out that the TPGs were mainly associated with extracellular matrix organization and immune response (**Figure 1C, 1D**). Not only did the enrichment results confirm that these genes were reliable to be related with the tumor purity, but it also laid solid foundations for the sequent analyses.

A prognostic model was constructed with three TPGs

With the 642 TPGs, we exerted PPI analysis to investigate their interaction and the hub genes (**Figure 2A**). The TPGs who had five or more interactive genes were shown in **Figure 2B,** and defined as hub genes. Then, we performed univariate Cox regression analysis to figure out the TPGs that were associated with the prognosis of DLBCL patients, and 103 genes were identified (**Figure 2C**). Interestingly, most of the TPGs were correlated with good outcome (with HR < 1), and only six genes were associated with poor outcome (with HR > 1). Through conducting intersection analysis, we found nine genes (LUM, VCAN, YAP1, COL5A2, SDC2, TWIST1, CD3G, C1QB and C3) were intersection genes, indicating that they had an active effect in modulating the tumor purity, as well as influencing the prognosis of DLBCL patients.

After ascertaining the key genes, we tried to construct a prognostic model with them. The model was constructed by Cox regression, and the three selected genes (VCAN, CD3G, C1QB) and their parameters like coefficient, HR and 95%CI of HR, were shown in **Figure 3A**. It showed that

VCAN and CD3G were correlated with good prognosis and C1QB was correlated with poor prognosis. All patients were divided into high and low-risk group according to the median value of riskScore (**Figure 3B**). As expected, the high-risk group has worse prognosis than the low-risk group (**Figure 3C**). In addition, the three genes were differentially expressed between high and low-risk group, with VCAN and CD3G showing high expression level in low-risk group, and C1QB showing high expression level in high-risk group, which was consistent with the coefficient (**Figure 3D**). To appraise the efficacy of these prognostic model, we conducted survival analysis and ROC analysis. High-risk group had lower OS rate than low-risk group (**Figure 3E**, $p < 0.001$), and the areas under curve (AUC) for 1-year, 3-year and 5-year ROC were 0.73, 0.77 and 0.77 respectively (**Figure 3F**). Just similar to tumor purity, the high riskScore indicated bad outcome, which was consistent with the positive correlation between tumor purity and riskScore (**Figure 3G**). This TPGs signature prognostic model manifested satisfying prognostic efficacy.

When we applied this model to GSE32918 dataset, it still did excellently and the results were in accordance with that in GSE53786 dataset (**Figure 4A, 4B; Supplementary Figure 2**). Next, we analyzed the relationship between riskScore and some clinicopathological characteristics provided in GSE53786 dataset. The results showed that high-risk group had more ABC type DLBCL, while low-risk group had more the GCB type DLBCL (**Figure 4C**). Besides, high-risk group displayed higher lactic dehydrogenase (LDH) ratio (**Figure 4F**). However, the Eastern Cooperative Oncology Group (ECOG) performance and stage was not associated with the riskScore (**Figure 4D, 4E**). Still, the high-risk group has more Stage III and Stage IV patients, but less Stage I patients than low-risk group. Finally, we employed the univariate and multivariate analysis to explore whether riskScore was an independent prognostic factor for DLBCL patients. As expected, the riskScore was associated with the poor prognosis (**Figure 4G**, $p < 0.001$, HR = 1.545, 95%CI 1.284–1.861) and was an independent prognostic factor (**Figure 4H**, $p = 0.002$, HR = 1.474, 95%CI 1.156–1.879).

The prognostic value of VCAN, CD3G and C1QB were validated by IHC assay

With the purpose of the further validation of the prognostic value of VCAN, CD3G and C1QB, we detected the expression of these genes in CHCAMS cohort by IHC. For VCAN, the patients were divided into high and low group according to the cut-off of the H-score (275.42) provided X-tile.

The survival analysis showed that patients with high expression of VCAN had higher OS rate

(**Figure 5A**, p = 0.003). For CD3G, previous study revealed that it was a component of T cell

receptor complex, for which it could be regarded as a marker of T cells. Therefore, we assessed

the expression level of CD3G by counting the CD3G+ T cells ratio, and divided patients by the

cut-off (2.5%). The survival analysis revealed that patients with high CD3G+ T cells infiltration

showed favorable prognosis (**Figure 5B**, p < 0.001). For C1QB, the patients in high expression

group (cut-off = 82.41) showed adverse prognosis (**Figure 5C**, p = 0.015). Although the detection

of protein level was not convenient to build a prognostic model for the difference of assessment

methods and the lake of coefficient, these results were in accordance with those of GEO datasets,

which successfully proved the prognostic value of VCAN, CD3G and C1QB.

Given that these genes could potentially influence the tumor purity of DLBCL, we then analyzed

the relationship between them and CD68+ macrophages, CD4+ T cells and CD8+ T cells. As was

shown in **Supplementary figure 3A**, CD68+ macrophages [(17.75±1.05) %] account for more

ratio than CD4+ T cells [(0.68±0.20) %] and CD8+ T cells [(6.69±0.56) %] (p < 0.001,

Kruskal-Wallis Test and Dunn's Test). In the survival analysis of these three types of immune cells,

we found that CD68+ macrophages, CD8+ T cells and CD4+ T cells were associated with better

prognosis (**Figure 5D–F**, p = 0.029, p = 0.002, p = 0.053). And XCELL and QUANTISEQ

algorithm revealed that M2 macrophages accounted for more proportion than M1 macrophages in

GSE53786 and GSE32918 (**Supplementary figure 3L-O**). Besides, the ratio of CD3G+ T cells

was positively correlated with that of CD68+ macrophages, CD8+ T cells and CD4+ T cells,

C1QB expression level was positively correlated with CD8+ T cells, and VCAN expression level

was positively correlated with CD8+ T cells ratio (**Figure 5G**).

In addition to the above analyses, we also explored the relationship between these three genes and

the proliferation and location of DLBCL. It turned out that CD3G+ T cells ratio was higher in

DLBCL originated from groin and testis, and VCAN featured higher expression in lymph node

originated DLBCL (**Figure 5H–I,** p < 0.05, p < 0.01**, Supplementary figure 3B–K**).

The TPGs signature model could also predict the drug sensitivity of DLBCL patients

In order to learn about the ability of the previously mentioned model to predict drug sensitivity,

we performed the prediction with "oncoPredict" package in R. Fifteen drugs (**Supplementary**

table 2) included in the GDSC and used in clinical practice or under clinical trials (searched on

Pubmed) were enrolled in this prediction analysis.

As is shown in **Figure 6A** (prediction of GSE53786), patients in high-risk group could be

sensitive to Carmustine, Cytarabine, Oxaliplatin, Vincristine, Vorinostat, and Bortezomib, but no

drug could work better in low-risk group. And in GSE32918 (**Figure 6B**), Carmustine, Cytarabine,

Oxaliplatin, Vorinostat, Afuresertib, Bortezomib, Ibrutinib and Tamoxifen could work better in

high-risk group, and Vincristine (sensitivity score: low-risk vs high-risk = 0.219±0.026 vs

0.223±0.031) could work better in low-risk group. The discrepancy between the prediction in two

datasets might be due to the samples and sequencing platforms. However, the intersection analysis

of the drugs to which the high-risk patients in both datasets could be sensitive revealed that

Carmustine, Cytarabine, Oxaliplatin, Vorinostat and Bortezomib could be reliable candidates for

treating high-risk patients based on the three TPGs signature prognostic model (**Supplementary**

table 2).

Discussion

In this study, bioinformatics techniques were employed to identify three genes (VCAN, CD3G,

C1QB) that exhibit associations with prognosis in both immune and stromal environments,

thereby revealing their relationship with the prognosis of DLBCL patients. The findings indicate

that higher expression of VCAN, increased infiltration of CD3G+ T cells, and decreased

expression of C1QB are correlated with favorable prognostic outcomes. Conversely, a lower

infiltration of CD68+ macrophages and lower infiltration of CD8+ T cells are associated with

poorer prognosis. Furthermore, we investigated the relationship between risk genes related to

tumor purity and treatment sensitivity and established a list of possible drugs that might be helpful

for enhancing outcomes.

Previous studies have extensively investigated the VCAN gene in relation to tumorigenesis and

metastasis[15]. VCAN, also known as versican, is a crucial component of extracellular matrix[16],

and exists in several isoforms[17]. Research has shown that VCAN plays a multifaceted role in

TME depending on the cell type expressing it. When expressed by myeloid cells, VCAN induces

an anti-inflammatory and immunosuppressive microenvironment. Conversely, its expression by

stromal cells typically leads to a pro-inflammatory response[18]. In gastric cancer, high expression of VCAN has been associated with increased infiltration of fibroblasts, significant enrichment of stromal-associated signaling pathways and poor prognosis[19]. In hepatocellular carcinoma, VCAN exhibits a strong association with immune checkpoint gene expression[20]. Despite these findings in other tumor types, the role of VCAN in DLBCL has not been explored yet. Our study reveals that high expression of VCAN is actually associated with a more favorable prognosis. This suggests that VCAN may have different functions in different tumor types. One possible mechanism through which VCAN influences prognosis is that VCAN overexpression in DLBCL may also impact tumor cell proliferation. A study has shown that overexpression of VCAN V1 has an inhibitory effect on cell proliferation, partly due to its promotion of activation-induced cell death in lymphoid cell lines[17]. Hence, the high expression of VCAN in DLBCL could impact not only the TME but also tumor cell proliferation, suggesting a potential mechanism for the observed preferable prognosis.

C1q is synthesized in the tumor microenvironment and functions as an extracellular matrix protein, and C1QB is a component of C1q[21]. Previous studies have provided insights into the diverse roles of C1q in cancer progression. However, the majority of these results, as observed in non-small cell lung carcinoma and gastric cancer, indicate that high C1q expression in TME is associated with a poor prognosis [22-24]. Additionally, C1QB has been found to exert an impact on the TME and is positively associated with infiltration levels of CD8+ T cell, as well as with M1 and M2 macrophages in osteosarcoma[25]. Moreover, C1QB expression shows a positive correlation with predictive biomarkers for immunotherapy, such as PD-L1 expression and CD8+ T cell infiltration[24]. Furthermore, in malignant melanoma, C1QB promotes proliferation, migration and invasion, while inhibiting cell apoptosis[26], and the high-expression group exhibits significant enrichment of genes related to immune and apoptosis[21]. In our study, we found that high expression of C1QB in DLBCL was associated with a worse prognosis and positively correlated with CD8+ T cells infiltration. Based on these findings, we propose that C1QB in DLBCL might share similarities with its functions in other tumor types, particularly regarding the promotion of recruitment and subsequent deactivation of CD8+ T cells within the TME through the induction of immune checkpoint effects. These results shed light on the intricate role of C1QB in TME and its potential significance as a prognostic marker in DLBCL.

CD3G is a member of the TCR/CD3 complex primarily expressed in lymphocytes subgroups. It plays a crucial role in initiating the activation of T cells[27]. It is also involved in coupling antigen recognition[28]. It is reported to associate with long-term OS and good prognosis in breast invasive carcinoma[29] as well as in head and neck squamous cell carcinoma[30]. However, its role in DLBCL has not been fully explored. In our study, we revealed that high infiltration of CD3G+ T cells is correlated with good prognosis. The infiltration of CD3G+ T cells was found to be positively related to the infiltration of CD8+, CD4+ and CD68+ cells. This indicates that CD3G+ T cells in DLBCL may enhance the tumor antigen recognition process and stimulate the infiltration of immune cells, leading to an increased abundance of immune cell infiltration in the TME. The presence of CD3G+ T cells in the TME may contribute to a favorable prognosis by facilitating the activation of immune responses against tumor cells.

Macrophages play a crucial role in TME, and CD68 is a surface marker specific to macrophages. Macrophages can be roughly classified into two types based on their functional features: M1 or M2. M1 macrophages exert anti-tumor effects, whereas M2 macrophages promote tumor growth and progression in TME[31]. A previous study found that low infiltration of CD68+ macrophages was associated with an inferior prognosis[32]. Similarly, our study has yielded similar results, revealing a noteworthy correlation between a high proportion of CD68+ macrophages in the TME and improved prognosis. Additionally, by analyzing the datasets, we observed a higher proportion of M1 macrophages infiltration compared to M2 macrophages. This suggests that, within our DLBCL cohort, these macrophages may also exhibit the M1 phenotype and consequently play a protective role against tumor progression.

CD8 is widely recognized as a marker of CD8+ T cells, also known as cytotoxic T cells[33]. These cells are crucial for the immune response against tumors. However, in DLBCL, CD8+ T cells exhibits elevated levels of inhibitory molecules on their surface, such as PD-1, PD-L1, TIM3. High expression of TIM3, an inhibitory immune checkpoint receptor, on CD8+ T cells has been associated with tumor progression and poor outcomes[34, 35]. These inhibitory molecules may impair the function of CD8+ T cells and hinder their anti-tumor activity. Surprisingly, our study demonstrates a correlation between the infiltration of CD8+ T cells and favorable prognosis in DLBCL. Here, we propose a hypothesis that in our study, the observed high expression of VCAN might create a suppressive environment for PD-1+ CD8+ T cells[18, 36]. Intriguingly, our study

revealed a statistically significant correlation between VCAN expression, C1QB expression and

CD8+ T cell infiltration. VCAN has the potential to modulate immune infiltration by reducing the

immunosuppressive phenotype of immune cells[37], thus enabling a more efficient anti-tumor

response. This aspect is still worth of consideration.

Taken together, our findings underscore the significant roles of VCAN, CD3G, C1QB, which

influence both the TME and the behavior of tumor cells. The interaction between each component

and the TME is rather complicated. To fully comprehend the underlying mechanisms and identify

potential therapeutic targets in DLBCL, further investigation is required.

However, this study still has several limitations that should be addressed. Firstly, the patients

included in this study were form a single center, which may introduce biases into the results.

Although we made efforts to minimize these biases, it is inevitable that some may persist.

Secondly, we hypothesized that VCAN, CD3G and C1QB could serve as continuous prognostic

parameters, thereby eliminating the need for a cut-off. However, the methodology used in this

study, which utilized IHC staining to assess the protein expression levels, may have potential

limitations. While IHC is a widely used technique, additional validation is needed to confirm the

prognostic value of VCAN, CD3G and C1QB in DLBCL. Furthermore, due to the potential

variability in interpreting IHC results across different centers, a standardized coefficient and

formula have not been established to calculate the final prognostic index for patients with DLBCL.

Developing a standardized approach would be beneficial in ensuring consistent and accurate

interpretation of IHC results. To address these limitations and expand upon our findings, future

studies should strive to incorporate a diverse range of patients from multiple centers. Additionally,

it is crucial to employ rigorous experimental techniques to authenticate the prognostic significance

of VCAN, CD3G, and C1QB in DLBCL.

Author contributions

Conceptualization: Wenting Huang, Ning Huang, Zhenbang Ye, Data Curation: Zhenbang Ye,

Ning Huang, Formal Analysis: Zhenbang Ye, Ning Huang, Investigation: Zhenbang Ye,

Methodology: Zhenbang Ye, Ning Huang, Wenting Huang, Resources: Wenting Huang, Yongliang

Fu, Supervision: Wenting Huang, Visualization: Zhenbang Ye, Ning Huang, Validation: Ning

Huang, Writing-Original Draft: Zhenbang Ye, Ning Huang, Writing-Review & Editing: Wengting

Huang, Yongliang Fu, Rongle Tian

Funding

This work is supported by Shenzhen High-level Hospital Construction Fund. The funders had no

role in study design, data collection and analysis, interpretation of data, or preparation of the

manuscript.

Acknowledgement

Conflicts of interest

The authors made no disclosures.

Figure 1 TPGs were screened out with GSE53786 dataset.

(A) The range (17.2 –67.4%) of tumor purity of samples in GSE53786. (B) The heatmap showing

genes defined as TPGs. (C) The K–M curve showed high tumor purity was correlated with poor

prognosis in DLBCL patients in GSE53678 dataset (Patients were divided into two groups

according to the best-cutoff provided by "survminer" package in R). (D) GO analysis of TPGs.

(E) KEGG analysis of TPGs. TPGs, tumor purity-related genes; K–M, Kaplan-Meier;

DLBCL, diffuse large B cell lymphoma; GO, gene ontology; KEGG, Kyoto Encyclopedia of

Genes and Genomes.

Figure 2 The key gene candidates used for constructing prognostic model were selected.

(A) The PPI network of TPGs (orange nodes representing genes positively correlated with

tumor purity, and green nodes representing genes negatively correlated with tumor purity). (B)

The barplot showing hub genes with five or more interactive genes. (C) The forest plot

showing prognostic TPGs of DLBCL patients in GSE53786. (D) The venn plot showing

intersection genes of PPI hub gene and prognostic TPGs. PPI, protein-protein interaction.

Figure 3 TPGs signature prognostic model was constructed.

(A) Three genes enrolled in the prognostic model. (B) The patients in GSE53786 dataset were

divided into high and low-risk group according to the median riskScore based on the

prognostic model. (C) High-risk group had worse prognosis than low-risk group. (D) The

heapmap showing expression discrepancy of the three genes. (E) Survival analysis revealed

that high-risk group had poor prognosis in GSE53786 dataset. (F) The ROC curve showed

that the prognostic model performed well in predicting 1-year, 3-year and 5-year prognosis in

GSE53786 dataset. (G) Tumor purity was positively correlated with riskScore in GSE53786

dataset. ROC, receiver operating characteristic.

Figure 4 The riskScore of three TPGs signature prognostic model was an independent

prognostic factor in DLBCL patients.

(A) Survival analysis results in GSE32918 dataset was consistent to that of GSE53786 dataset.

(B) The prognostic model also did well in GSE32918 dataset. (C) High-risk group in

GSE53786 dataset contained more ABC type DLBCL, while low-risk group contained more

GCB type DLBCL. (D) The ECOG performance of two groups (GSE53786 dataset) showed

no statistical difference. (E) More patients in high-risk group were at Stage III or Stage IV,

and less patients were at Stage I, compared with low-risk group, although no statistical

significance was shown (GSE53786 dataset). (F) High-risk group had higher LDH ratio

(GSE53786 dataset). (G) The riskScore was associated with poor prognosis of DLBCL

patients in GSE53786 dataset. (H) The riskSocre was an independent prognostic factor for

DLBCL patient. * $p < 0.05$, ** $p < 0.01$, ns, not significant. ABC, activated B cell; GCB,

germinal center B cell; ECOG, Eastern Cooperative Oncology Group; LDH, lactic

dehydrogenase.

Figure 5 The analysis of CHCAMS cohort.

(A) The representative image of VCAN staining of high and low expression groups and the

survival analysis based on VCAN expression. (B) The representative image of CD3G staining

of high and low CD3G+ T cells ratio groups and the survival analysis based on CD3G+ T

cells ratio. (C) The representative image of C1QB staining of high and low expression group

and the survival analysis based on C1QB expression. (D) The representative image of CD68

staining of high and low CD68+ macrophages ratio groups and the survival analysis based on

CD68+ macrophages ratio. (E) The representative image of CD8 staining of high and low

CD8+ T cells ratio groups and the survival analysis based on CD8+ T cells ratio. (F) The

representative image of CD4 staining of high and low CD4+ T cells ratio groups and the

survival analysis based on CD4+ T cells ratio. (G) The correlation between VCAN, CD3G+ T

cells ration, C1QB and CD68+ macrophages, CD8+ T cells and CD4+ T cells ratio. "×"

means no statistical significance. (H) The CD3G+ T cells infiltration varied from colon to

testis originating DLBCL in male. (I) The VCAN expression level was different between

intra- and extra-lymph node DLBCL.

Figure 6 Drug sensitivity prediction revealed therapeutic candidates for high-risk group.

(A) Drug sensitivity prediction results with statistical significance in GSE53786 dataset. (B)

Drug sensitivity prediction results with statistical significance in GSE53786 dataset.

Supplementary Figure 1 Flow chart and study design of this research.

Supplementary Figure 2 The correlation between tumor purity and prognosis and

riskScore in GSE32918 dataset.

(A) High ESTIMATE-Score group had better prognosis. (B) ESTIMATE-Score was

negatively associated with riskScore. Note: ESTIMATE-Score manifests the tumor purity,

with high ESTIMATE-Score indicating low tumor purity and high immune and stromal

components. Because the GSE32918 datasets were sequenced with illumina platform, the

ESTIMATE algorithm only provided ESTIMATE Score to represent the tumor purity.

Supplementary Figure 3 The immunoenvironment analysis and clinicopathological

analysis of CHCAMS cohort and GEO datasets.

(A) The ratio of CD68+ macrophages, CD8+ T cells and CD4+ T cells in CHCAMS cohort.

(B–D) The correlation between VCAN, CD3G+ T cells, C1QB and types of DLBCL in

CHCAMS cohort. (E–K) The correlation between VCAN, CD3G+ T cells, C1QB and

DCBCL origination in CHCAMS cohort. "Location to LN" means the relative location of the

tumor to lymph node, that is, intra-lymph node or extra-lymph node. (L–M) The predicted M1

and M2 macrophages proportion in GSE53786 dataset. (N–O) The predicted M1 and M2

macrophages proportion in GSE32918 dataset. **p < 0.01, ***p < 0.001.

References:

1.   Alaggio, R., et al., *The 5th edition of the World Health Organization Classification of*

Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia, 2022. **36**(7): p.

1720-1748.

2.   Sehn, L.H. and G. Salles, *Diffuse Large B-Cell Lymphoma.* N Engl J Med, 2021.

384(9): p. 842-858.

3.   Autio, M., et al., *Immune cell constitution in the tumor microenvironment predicts the*

outcome in diffuse large B-cell lymphoma. Haematologica, 2021. **106**(3): p. 718-729.

4.   Joyce, J.A. and J.W. Pollard, *Microenvironmental regulation of metastasis.* Nat Rev

Cancer, 2009. **9**(4): p. 239-52.

5.   Steen, C.B., et al., *The landscape of tumor cell states and ecosystems in diffuse large*

B cell lymphoma. Cancer Cell, 2021. **39**(10): p. 1422-1437.e10.

6.   Ciavarella, S., et al., *Dissection of DLBCL microenvironment provides a gene*

expression-based predictor of survival applicable to formalin-fixed paraffin-embedded

tissue. Ann Oncol, 2018. **29**(12): p. 2363-2370.

7.   Ennishi, D., et al., *Toward a New Molecular Taxonomy of Diffuse Large B-cell*

Lymphoma. Cancer Discov, 2020. **10**(9): p. 1267-1281.

8.   Miyawaki, K., et al., *A germinal center-associated microenvironmental signature*

reflects malignant phenotype and outcome of DLBCL. Blood Adv, 2022. **6**(7): p.

2388-2402.

9.   Schmitz, R., et al., *Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.* N

Engl J Med, 2018. **378**(15): p. 1396-1407.

10.   Lou, X., et al., *CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma*

via M2 macrophage interactions: A bioinformatic analysis of the tumor

microenvironment. Front Immunol, 2022. **13**: p. 950213.

11.   Gong, Z., J. Zhang, and W. Guo, *Tumor purity as a prognosis and immunotherapy*

relevant feature in gastric cancer. Cancer Med, 2020. **9**(23): p. 9052-9063.

12.   Lou, S., et al., *Comprehensive Characterization of Tumor Purity and Its Clinical*

Implications in Gastric Cancer. Front Cell Dev Biol, 2021. **9**: p. 782529.

13.   Zhao, Y., et al., *Tumor purity-associated genes influence hepatocellular carcinoma*

prognosis and tumor microenvironment. Front Oncol, 2023. **13**: p. 1197898.

14.   Zhang, C., et al., *Tumor Purity as an Underlying Key Factor in Glioma.* Clin Cancer

Res, 2017. **23**(20): p. 6279-6291.

15.   Baghy, K., et al., *Proteoglycans in liver cancer.* World J Gastroenterol, 2016. **22**(1): p.

379-93.

16.   Wight, T.N., *Provisional matrix: A role for versican and hyaluronan.* Matrix Biol, 2017.

60-61: p. 38-56.

17.   Fujii, K., et al., *Versican upregulation in Sézary cells alters growth, motility and*

resistance to chemotherapy. Leukemia, 2015. **29**(10): p. 2024-32.

18.   Wight, T.N., et al., *Versican-A Critical Extracellular Matrix Regulator of Immunity and*

Inflammation. Front Immunol, 2020. **11**: p. 512.

19.   Song, J., et al., *Versican enrichment predicts poor prognosis and response to*

adjuvant therapy and immunotherapy in gastric cancer. Front Immunol, 2022. **13**: p.

960570.

20.   Wang, M.Q., et al., *VCAN, expressed highly in hepatitis B virus-induced hepatocellular*

carcinoma, is a potential biomarker for immune checkpoint inhibitors. World J

Gastrointest Oncol, 2022. **14**(10): p. 1933-1948.

21.   Yang, H., et al., *Prognostic and immune-related value of complement C1Q (C1QA,*

C1QB, and C1QC) in skin cutaneous melanoma. Front Genet, 2022. **13**: p. 940306.

22.   Li, Z., et al., *Differentiation-related genes in tumor-associated macrophages as*

potential prognostic biomarkers in non-small cell lung cancer. Front Immunol, 2023.

14: p. 1123840.

23.   Mangogna, A., et al., *Prognostic Implications of the Complement Protein C1q in*

Gliomas. Front Immunol, 2019. **10**: p. 2366.

24.   Jiang, J., et al., *Identification of TYROBP and C1QB as Two Novel Key Genes With*

Prognostic Value in Gastric Cancer by Network Analysis. Front Oncol, 2020. **10**: p.

1765.

25.   Chen, L.H., et al., *Complement C1q (C1qA, C1qB, and C1qC) May Be a Potential*

Prognostic Factor and an Index of Tumor Microenvironment Remodeling in

Osteosarcoma. Front Oncol, 2021. **11**: p. 642144.

26.   Zheng, Y., et al., *IRF4-activated TEX41 promotes the malignant behaviors of*

melanoma cells by targeting miR-103a-3p/C1QB axis. BMC Cancer, 2021. **21**(1): p.

1339.

27.   Wang, M., D. Windgassen, and E.T. Papoutsakis, *Comparative analysis of*

transcriptional profiling of CD3+, CD4+ and CD8+ T cells identifies novel immune

response players in T-cell activation. BMC Genomics, 2008. **9**: p. 225.

28.   Chen, Z., et al., *A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype.* Front Immunol, 2021. **12**: p. 749459.

29.   Wang, Q., P. Li, and W. Wu, *A systematic analysis of immune genes and overall survival in cancer patients.* BMC Cancer, 2019. **19**(1): p. 1225.

30.   Wang, J., et al., *Establishment and validation of immune microenvironmental gene signatures for predicting prognosis in patients with head and neck squamous cell carcinoma.* Int Immunopharmacol, 2021. **97**: p. 107817.

31.   Zhang, Y., et al., *GM-CSF enhanced the effect of CHOP and R-CHOP on inhibiting diffuse large B-cell lymphoma progression via influencing the macrophage polarization.* Cancer Cell Int, 2021. **21**(1): p. 141.

32.   Croci, G.A., et al., *SPARC-positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double-/triple-hit status.* Ann Oncol, 2021. **32**(11): p. 1400-1409.

33.   Farhood, B., M. Najafi, and K. Mortezaee, *CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: A review.* J Cell Physiol, 2019. **234**(6): p. 8509-8521.

34.   Roussel, M., et al., *Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade.* Blood Adv, 2021. **5**(7): p. 1816-1829.

35.   Xu-Monette, Z.Y., et al., *Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.* Cancer Immunol Res, 2019. **7**(4): p. 644-657.

36.   Hirani, P., et al., *Targeting Versican as a Potential Immunotherapeutic Strategy in the Treatment of Cancer.* Front Oncol, 2021. **11**: p. 712807.

37.   Huang, X.Y., et al., *Bioinformatics analysis of the prognosis and biological significance*

of VCAN in gastric cancer. Immun Inflamm Dis, 2021. **9**(2): p. 547-559.